10 Diabetic retinopathy (DR), occurred in 22% of diabetes patients and 6% suffer from vision threatening DR which might lead to irreversible vision impairment even blindness
SUSTAIN-6 showed a 26% reduction in 3P-MACE in a secondary prevention population, prompting the FDA to expand indications for injectable semaglutide to include reducing risk of cardiovascular events in patients with T2DM and established CVD (60)
Topline The use of GLP-1 medications like semaglutide for weight loss has increased twofold over the past decade, but declined in use among those with type 2 diabetes, according to a new study, and the researchers warn the resulting and ongoing drug shortage may limit the access people with diabetes have to the drugs
Verrina E, Caruso U, Calevo MG, Emma F, Sorino P, De Palo T et al (2007) Effect of carnitine supplementation on lipid profile and anemia in children on chronic dialysis
By triggering the release of adrenocorticotropic hormone (ACTH), it plays a vital role in how our body responds to stress and maintains balance in various metabolic processes
GLP-1 injections not only manage type 2 diabetes but also support weight loss through various mechanisms: Promoting Fullness: By stimulating receptors in the brain, GLP-1 injections enhance feelings of satiety and reduce appetite, leading to decreased food consumption